Health Condition 1: B359- Dermatophytosis, unspecified
Conditions
Interventions
Intervention1: Griseofulvin: group A - griseofulvin 10 mg/kg body weight in two divided doses per day, for a period of 6 weeks.
Control Intervention1: Terbinafine: Group B - terbinafine 5 mg /kg body
Sponsors
Maharajahs institute of medical sciences
Eligibility
Inclusion criteria
Inclusion criteria: 1. Clinically diagnosed cases of recurrent dermatophytoses infection with at least one episode of relapse with 4Â weeks of completing the recommended duration of anti fungal therapy. 2. Both sexes between the age groups 18 - 70 yrs.
Exclusion criteria
Exclusion criteria: 1. Infants, patients below 18 years and above 70 years 2. Immunocompromised patients (HIV). 3. Pregnant and lactating females. 4. Patients receiving multiple drugs (glucocorticoids, statins, etc.) for other medical conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Clinical profile of recurrent dermatophytic infections prevalent in this region will be recorded. 2. The mycological profile and histopathological profile in recurrent dermatophytosis will be recorded. 3. Therapeutic efficacy of single and combinations of systemic antifungal drugs in recurrent dermatophytic infections will be reported.Timepoint: 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To note recurrences in the follow up period of 3 monthsTimepoint: 3 months | — |
Countries
India
Contacts
Public ContactUrmila Yellamelli
Maharajahs institute of medical sciences
Outcome results
None listed